27/06/2016 00:01:24 1-888-992-3836 (toll free) Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
06/24/20168:00AMBWMerck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29
Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its second-quarter 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Friday, July 29. During the call, company executives will provide an overview of Merck’s performance for the quarter... More...>>
06/22/201611:50AMDJNMARKET SNAPSHOT: U.S. Stocks Try To Extend Gains To 3rd Day Ahead Of Brexit Vote
By Ellie Ismailidou and Victor Reklaitis, MarketWatch Fed's Yellen sees 'mixed developments' in the economy; Tesla shares dive after bid for SolarCity U.S. stocks climbed Wednesday for a third straight session, joining a global stock rally boosted by expectations that the U.K. will vote in favor of remaining... More...>>
06/20/201612:30PMBWResults of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in Combination with Imipenem/Cilast...
Pivotal Phase 3 Studies Ongoing in Treatment of Serious Bacterial Infections Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that a Phase 2 study of relebactam, the company’s investigational beta-lactamase inhibitor, in combination with imipenem/cilastatin (an approved carbapenem... More...>>
06/16/20165:08PMDJNMARKET SNAPSHOT: Stocks Snap 5-day Losing Streak; Dow Reverses Triple-digit Loss
By Ellie Ismailidou and William Watts, MarketWatch Both sides in Brexit campaign suspend activity after U.K. lawmaker's death U.S. stocks erased early losses to close modestly higher on Thursday, ending a five-day streak of losses. For the past several sessions, a British referendum scheduled for June 23 to decide... More...>>
06/16/20164:37PMDJNMARKET SNAPSHOT: Stocks Snap 5-day Losing Streak; Dow Reverses Triple-digit Loss
By Ellie Ismailidou and William Watts, MarketWatch Both sides in Brexit campaign suspend activity after U.K. lawmaker's death U.S. stocks erased early losses to close modestly higher on Thursday, ending a five-day streak of losses. For the past several sessions, a British referendum scheduled for June 23 to decide... More...>>
06/16/201612:44PMDJNMARKET SNAPSHOT: U.S. Stocks Fall As Investors Worry About Brexit Vote
By Ellie Ismailidou and Sara Sjolin, MarketWatch Global equities fall; BOE, BOJ leave rates unchanged U.S. stocks fell Thursday, leaving them on track for their sixth straight daily drop and the longest losing streak since February, as investors worried about next week's so-called Brexit referendum along with concerns... More...>>
06/16/201611:09AMDJNMARKET SNAPSHOT: U.S. Stocks Head For 6th Daily Drop Amid Global Flight To Safety
By Ellie Ismailidou and Sara Sjolin, MarketWatch 'Brexit' fears take over global markets; BOE, BOJ leave rates unchanged U.S. stocks tumbled Thursday, joining a global stock selloff fueled by fears about next week's so-called Brexit referendum along with concerns about slowing global economic growth. The... More...>>
06/16/201610:00AMDJNMARKET SNAPSHOT: Dow Industrials Drop 113 Points As Brexit Fears Grow
By Ellie Ismailidou and Sara Sjolin, MarketWatch Consumer Price Index misses expectations; BOE, BOJ leave rates unchanged U.S. stocks opened lower Thursday--on track for their sixth straight daily drop and the longest losing streak since February--after the Federal Reserve, the Bank of England and the Bank of Japan raised... More...>>
06/16/20168:00AMBWSystematic Review of 58 Publications of Real-World Use of GARDASIL® Presented at EUROGIN Congress
Studies Published over the Last 10 Years Report Reductions in Cervical Pre-cancers and Other HPV-related Diseases Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that in a systematic review conducted of the global impact and effectiveness of GARDASIL® [Human Papillomavirus Quadrivalent... More...>>
06/16/20166:45AMBWMerck’s KEYTRUDA® (pembrolizumab) Demonstrates Superior Progression-Free & Overall Survival Compared to Chemotherapy as F...
KEYNOTE-024 Studied Patients Whose Tumors Expressed High Levels of PD-L1 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the KEYNOTE-024 trial investigating the use of KEYTRUDA® (pembrolizumab), in patients with previously untreated advanced non-small cell lung cancer (NSCLC... More...>>
06/15/20168:30AMBWMerck Highlights Ongoing Commitment to Fighting Infectious Diseases with More than 30 Data Presentations at ASM Microbe 2016
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that researchers are scheduled to provide more than 30 scientific data presentations on the company’s established and investigational infectious disease medicines and vaccines at the American Society for Microbiology’s ASM Microbe... More...>>
06/14/20162:00AMPRNUSNew Data From GAP Landmark Trial Confirm GRAZAX® Significantly Reduces Asthma Symptoms in Children
New Data From GAP Landmark Trial Confirm GRAZAX® Significantly Reduces Asthma Symptoms in Children PR Newswire HØRSHOLM, Denmark, June 14, 2016 HØRSHOLM, Denmark, June 14, 2016 /PRNewswire/ -- Treatment benefit increased over time. In the two years after treatment completion, the estimated risk of experiencing asthma... More...>>
06/13/201611:00AMPRNUSNew Data From GAP Landmark Trial Confirm GRAZAX® Prevents Asthma Symptoms in Children
New Data From GAP Landmark Trial Confirm GRAZAX® Prevents Asthma Symptoms in Children PR Newswire HØRSHOLM, Denmark, June 13, 2016 HØRSHOLM, Denmark, June 13, 2016 /PRNewswire/ -- Treatment benefit increased over time. In the two years after treatment completion, the estimated risk of experiencing asthma symptoms nearly... More...>>
06/13/201610:30AMBWMerck’s Investigational Insulin Glargine, MK-1293, Met Primary Endpoint in Two Phase 3 Studies, Showing Non-Inferiority to ...
Data in Patients with Type 1 and Type 2 Diabetes Presented for the First Time at the 76th Scientific Sessions of the American Diabetes Association Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from two Phase 3 studies evaluating MK-1293, Merck’s investigational, follow-on... More...>>
06/11/201611:00AMBWMerck & Pfizer Announce Two Pivotal Phase 3 Studies for Ertugliflozin, an Investigational SGLT-2 Inhibitor, Met Primary Endpo...
Ongoing CV Outcomes Trial of Ertugliflozin Expanded to Test for Superiority in CV Risk Reduction Merck (NYSE:MRK), known as MSD outside the United States and Canada, in partnership with Pfizer Inc. (NYSE:PFE), today announced that two Phase 3 studies (VERTIS Mono and VERTIS Factorial) of ertugliflozin, an investigational... More...>>
06/09/20167:07PMDJNMerck to Acquire Biotech Company Afferent -- Update
By Josh Beckerman Merck & Co. has agreed to purchase biotechnology company Afferent Pharmaceuticals, whose lead drug candidate is being evaluated as a treatment for refractory, chronic cough and idiopathic pulmonary fibrosis with cough. The deal will include an upfront payment of $500 million and milestones of up to... More...>>
06/09/20166:50PMDJNMerck to Acquire Biotech Company Afferent
Merck & Co. has agreed to purchase biotechnology company Afferent Pharmaceuticals, whose lead drug candidate is being evaluated as a treatment for refractory, chronic cough and idiopathic pulmonary fibrosis with cough. The deal will include an upfront payment of $500 million and milestones of up to $750 million. San... More...>>
06/09/20166:34PMBWMerck to Acquire Afferent Pharmaceuticals
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this privately held pharmaceutical company. Afferent Pharmaceuticals is a leader in the development of therapeutic candidates... More...>>
06/09/20166:29PMDJNMerck to Acquire Biotech Company Afferent
By Josh Beckerman Merck & Co. has agreed to purchase biotechnology company Afferent Pharmaceuticals, whose lead drug candidate is being evaluated as a treatment for refractory, chronic cough and idiopathic pulmonary fibrosis with cough. The deal will include an upfront payment of $500 million and milestones of up to... More...>>
06/09/20165:07PMBWMerck to Acquire Afferent Pharmaceuticals
Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this privately held pharmaceutical company. Afferent Pharmaceuticals is a leader in the development of therapeutic candidates... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V:us D:20160627 04:01:25